FOMAT is a leading oncology clinical trial site California, now expanding its research portfolio with a dedicated oncology unit at its headquarters in Oxnard, Ventura County. This initiative brings community based cancer trials directly to local patients, offering access to innovative treatments without the burden of long distance travel. By adding oncology to its therapeutic offerings, FOMAT aims to accelerate the development of advanced cancer therapies for diverse and underrepresented communities.
Cancer remains one of the leading causes of morbidity and mortality worldwide, making it a critical focus for clinical research. As an established oncology clinical trial site California, FOMAT is positioned to contribute to groundbreaking treatments that improve patient outcomes, particularly for populations historically underrepresented in clinical studies.
Oncology Clinical Trial Site California: Benefits for Patients and Sponsors
For industry sponsors and CROs seeking a reliable oncology clinical trial site California, FOMAT offers a proven integrated model with fast enrollment, diverse patient populations, and an established site network across Ventura and surrounding counties. This expansion was accelerated by a request from one of FOMAT’s top 10 pharmaceutical partners, who sought to replicate the speed and effectiveness FOMAT has demonstrated across other therapeutic areas.
For patients, participation in a local oncology trial means access to cutting edge cancer treatments that might not otherwise be available nearby. FOMAT’s community based approach reduces participation barriers and reflects the diverse demographics of the region, including White Hispanic, Multiracial Hispanic, Asian Non Hispanic, and Multiracial Non Hispanic populations.
Principal Investigators also benefit from access to FOMAT’s site resources and network, enhancing their ability to conduct high quality oncology trials and contribute to therapies that work across diverse patient groups. The depth of FOMAT’s investigator network and its established infrastructure make it a reliable partner for complex oncology studies requiring fast startup and consistent patient access.
The Vision Behind the Expansion
Nicholas Focil, CEO of FOMAT, highlighted the strategic intent: “A recent request from one of our top 10 pharmaceutical company clients confirmed and accelerated our existing plans to add community based oncology trials to our research portfolio. They sought to replicate the speed and effectiveness we have demonstrated across other therapeutic areas.”
The first oncology trial launched in partnership with Dr. Nawazish Khan, an oncologist with over two decades of experience in cancer and pharmaceutical clinical development. Dr. Khan’s work centers on improving health outcomes through greater access to innovative treatments and diverse trial participation. His expertise in oncology and community engagement makes him an ideal partner for this initiative.
Expanding Access for Diverse Communities
FOMAT’s role as a community-based oncology clinical trial site California is central to its mission of inclusivity. By conducting trials close to home, FOMAT reduces logistical barriers and ensures that research reflects the real world diversity of its patient populations, producing data that leads to more broadly effective therapies. Reaching underrepresented communities is not just a goal but a core part of how FOMAT operates.
FOMAT’s commitment to inclusivity extends beyond enrollment numbers. The organization actively works with community leaders, local health providers, and patient advocacy groups to raise awareness about available oncology trials. This outreach ensures that patients who could benefit most from participating in an oncology clinical trial site California are informed and supported throughout the process, from initial screening to study completion.
A Collaborative Path Forward
The partnership between FOMAT and Dr. Khan exemplifies collaborative, patient centered research. Together they aim to bring advanced cancer treatments to Ventura County and surrounding areas, giving patients access to the latest innovations in oncology care.
“Partnering with FOMAT allows me to continue my work in developing and delivering innovative cancer treatments. I am honored to be part of an organization that values diversity and inclusivity in clinical research,” Dr. Khan said.
To learn more about how this collaboration is poised to transform oncology care in Ventura and beyond, read the full press release here.